Kepivance (Palifermin)
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Non-Hodgkin's Lymphoma
Conditions
Non-Hodgkin's Lymphoma, Multiple Myeloma
Trial Timeline
Apr 1, 2006 โ May 1, 2007
NCT ID
NCT00352703About Kepivance (Palifermin)
Kepivance (Palifermin) is a approved stage product being developed by Swedish Orphan Biovitrum for Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00352703. Target conditions include Non-Hodgkin's Lymphoma, Multiple Myeloma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00352703 | Approved | Completed |
Competing Products
20 competing products in Non-Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| LY317615 | Eli Lilly | Phase 2 | 52 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 33 |
| Bortezomib + Rituximab + Rituximab | Johnson & Johnson | Phase 3 | 77 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR1459 ๏ผYY-20394 + SHR1459 ๏ผYY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 33 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 33 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 33 |
| ABT-199 + Rituximab + Bendamustine | AbbVie | Phase 1 | 33 |
| ABBV-291 | AbbVie | Phase 1 | 33 |
| ABT-199 | AbbVie | Phase 1 | 33 |
| Avelumab | Merck | Phase 1 | 33 |